Taiwanese Drugmaker's New Therapy Approved by US FDA for ET Patients

PharmaEssentia, a Taiwanese drug developer, has secured US Food and Drug Administration (FDA) approval for its new drug Ropeg to treat essential thrombocythemia (ET). This landmark decision covers all ET patients, including those newly diagnosed who have not yet undergone reduction therapy. The approval is expected to benefit an estimated 170,000 ET patients across the United States.

Ropeg's FDA approval signifies a major advancement, achieving three "firsts": it is the first drug approved for all adult ET patients, regardless of prior treatment history; it is the first drug usable by patients irrespective of their previous treatments; and it is the first interferon therapy specifically developed for ET. This marks the first new drug approval for ET in the US in nearly three decades.

This new indication for Ropeg positions it as a significant player in the myeloproliferative neoplasms (MPN) market. The drug is already approved in approximately 50 countries for treating polycythemia vera (PV), another MPN. Ropeg is a novel, long-acting interferon developed and manufactured by PharmaEssentia. The company anticipates that the ET approval will add substantial growth momentum to its global MPN business.

PharmaEssentia has been strategically preparing for the US ET market launch. The company held a marketing conference in Chicago in mid-August to align its sales and marketing teams and finalize launch strategies. With a robust supply chain in place and building on the existing market presence for Ropeg in PV, PharmaEssentia plans to initiate comprehensive marketing activities across the US to rapidly increase market penetration for the ET indication.

The company has also seen progress in global approvals for Ropeg's ET indication. Taiwan approved the drug in May for adult ET patients resistant or intolerant to hydroxyurea, and Japan followed with approval for all adult ET patients in late August. Ropeg has been granted orphan drug exclusivity by the FDA for ET, providing seven years of market exclusivity in the US upon formal approval, further strengthening its competitive position.

“

Ropeg's FDA approval marks the first time in nearly 30 years a new drug has been approved for ET and is the first interferon therapy specifically for ET.